SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
SABSW 10.31.2024
About Gravity Analytica
Recent News
- 01.23.2025 - SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
- 11.06.2024 - SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
- 10.31.2024 - SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
Recent Filings
MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Chairman and CEO Samuel J. Reich will be speaking at an upcoming fireside chat at the 2024 Guggenheim Securities Healthcare Innovation Conference held November 11th– 13th, 2024 in Boston, MA.
Event Details: Monday, November 11, 2024 at 3:00pm ESTLocation: Boston, MAWebcast Registration Link:https://wsw.com/webcast/guggen/sabs/1934789
A recording of the webcast will be accessible through the “Events” section of the Company’s website athttps://ir.sab.bio/news-events/events.
About SAB BIO
SAB BIO (SAB) is a clinical-stage biopharmaceutical company focused on developing human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company’s lead asset, SAB-142, targets T1D with a disease-modifying therapeutic approach that aims to change the treatment paradigm by delaying onset and potentially preventing disease progression. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) BovineTM, the only transgenic animal with a human artificial chromosome, SAB’s DiversitAbTM drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, human IgGs that can address a wide range of serious unmet needs in human diseases without the need for convalescent plasma or human donors. For more information on SAB, visit:www.SAB.bioand follow SAB onLinkedIn.
Forward-Looking Statements
Certain statements made in this current report that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “to be,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including, the development and efficacy of our T1D program and other discovery programs.
These statements are based on the current expectations of SAB and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
CONTACTS
Media Relations:
Kaelan Hollonkhollon@sab.bioVice President of Communications
Investor Relations:
Kevin GardnerLifeSci Advisorskgardner@lifesciadvisors.com
Chris CalabreseLifeSci Advisorsccalabrese@lifesciadvisors.com
